<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829149</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROZ-OS-01</org_study_id>
    <nct_id>NCT04829149</nct_id>
  </id_info>
  <brief_title>Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea</brief_title>
  <official_title>A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe)&#xD;
      Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the effect of reducing LDL-C levels after 12&#xD;
      months of administration of Statin Monotherapy or Rosuzet Tab.(Rosuvastatin/Ezetimibe) in&#xD;
      patients with dyslipidemia in Korea&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>12 months</time_frame>
    <description>LDL-C percentage of change in Statin therapy group and Rosuzet group from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>6 months</time_frame>
    <description>LDL-C percentage of change in Statin therapy group and Rosuzet group from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>6, 12 months</time_frame>
    <description>Triglyceride, HDL-C, Total Cholesterol percentage of change in Statin therapy group and Rosuzet group from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and aspect of new onset diabetes and adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence and aspect of new onset diabetes and adverse events in Statin therapy group and Rosuzet group during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescription rate</measure>
    <time_frame>12 months</time_frame>
    <description>Prescription rate of Statin therapy group and Rosuzet group during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for medication change</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of Rate on reason for medication change in Statin therapy group and Rosuzet group during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>12 months</time_frame>
    <description>MPR(medication possession ratio) of Statin therapy group and Rosuzet group during the study period</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5717</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Statin therapy group (No interventional)</arm_group_label>
    <description>Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuzet tablet group (No interventional)</arm_group_label>
    <description>Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Statin therapy group and Rosuzet tablet group</description>
    <arm_group_label>Rosuzet tablet group (No interventional)</arm_group_label>
    <arm_group_label>Statin therapy group (No interventional)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A Korean dyslipidemia patient who is taking or is scheduled to take statins therapy or&#xD;
        Rosuzet tablets&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ageâ‰¥19&#xD;
&#xD;
          2. Subject who is taking or is scheduled to take Statins therapy or Rosuzet Tab.&#xD;
&#xD;
          3. Not diagnosed with diabetes&#xD;
&#xD;
          4. Subject who can written informed consent voluntarily&#xD;
&#xD;
          5. Subject can continue to participate for 12 months on Study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients for whom use of Rosuzet Tab. and Statin therapy is prohibited (e.g. patient&#xD;
             who are hypersensitive to the main or compositional component of this drug, patient&#xD;
             with active liver disease, patient with severe renal failure, patient using&#xD;
             combinations with cyclosporin)&#xD;
&#xD;
          2. A pregnant or nursing woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi-Jeung KIM</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi Pharmaceutical Company Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanmi Pharmaceutical Company Limited</name>
      <address>
        <city>Seoul</city>
        <zip>05545</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>New onset DM</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

